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Abstract To assess the potential involvement of the caspase 
family in the IL-3-dependent murine myeloid leukemic cell line 
32D, we studied the effect of bcl-2, crmA and three synthetic 
caspase inhibitors on apoptosis induced by chemotherapy or IL-3 
withdrawal. Apoptosis induced by IL-3 deprivation or by ActD 
appears to be mediated by a crmA-insensitive pathway. Cell 
death by IL-3 withdrawal is inhibited by the caspase-inhibitor 
ZVAD-fmk, but not DEVD-fmk or YVAD-cmk. In contrast, 
DEVD-fmk as well as ZVAD-fmk protect 32D cells from ActD-
induced apoptosis. These results indicate that different caspases 
are involved in apoptosis induced by growth factor withdrawal 
and by chemotherapy. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The biochemical pathways leading to apoptosis remain 
poorly understood. However, the recent demonstrat ion that 
the nematode death gene ced-3 encodes a cysteine protease 
related to the mammalian interleukin-1-ß converting enzyme 
(ICE) has led to the identification of a large family of cysteine 
proteases (caspases) which, on the basis of phylogenetic anal-
ysis, can be divided into three subfamilies: the CASP-1 sub-
family (CASP-1, -4, -5, -11, -12), the CASP-3 subfamily 
(CASP-3, -6, -7, -8, -10) and a third family which only con-
tains CASP-2 and CASP-9 [1-5]. Transient overexpression of 
each member of the human and murine caspase families in-
duces apoptosis in mammalian cells. Convincing evidence for 
a functional role of the caspase family in Fas- and T N F -
mediated apoptosis of eukaryotic cells has come from studies 
with the viral encoded caspase inhibitors crmA and baculovi-
rus p35 and the use of pep tide-based synthetic inhibitors of 
the caspase family [6-10]. In contrast, only few studies have 
been performed to analyze the role of the caspase family in 
apoptosis of growth factor-dependent leukemic cells [11]. 
The present studies show that apoptosis of murine IL-3-
dependent myeloid leukemic cells (32D) induced by actinomy-
cin D (ActD) or growth factor deprivation is mediated by a 
crmA-insensitive mechanism. In addition, we demonstrate 
that different caspases are involved in apoptotic death induced 
by either ActD or IL-3 deprivation. 
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2. Materials and methods 
The protease inhibitors ZVAD-fmk and DEVD-fmk were pur-
chased from Enzyme Systems Products (Dublin, CA). Ac-YVAD-
cmk from Calbiochem (Cambridge, MA). The substrates N-acetyl-
YVAD-pNA and JV-acetyl-DEVD-pNA were obtained from Biomol 
(Plymouth Meeting, PA). ActD and puromycin were obtained from 
Sigma Chemicals Co. (St. Louis, MO). The XTT test was purchased 
from Boehringer-Mannheim. Murine IL-3 was kindly provided by 
Sandoz (Vienna, Austria). FITC-labeled Annexin V was obtained 
from Bender and Co. (Vienna, Austria). 
2.1. Cell culture and transfections 
The IL-3-dependent murine leukemic cell line 32D was maintained 
in RPMI-1640 medium supplemented with 10% fetal calf serum and 
10% WEHI-3B cell-conditioned medium as a source of murine IL-3. 
CrmA-expressing 32D cells were generated by cotransfection of 8 μg 
of pCAGGS-CrmA [12] and 1.8 μ£ pBSpacdp (puromycin) by electro-
poration. Stable transfectants were selected in the presence of 1 μ^ηιΐ 
puromycin. Positive crmA clones were identified by Western blotting. 
The isolation and characterization of 32D+bcl-2 cells has been de-
scribed previously [13]. 
2.2. Induction and analysis of apoptosis 
In experiments analyzing apoptosis, cells were washed 3 times and 
resuspended at 5X10° cells/ml in the presence or absence of IL-3 
(10 ng/ml) or ActD (1 \iglmX). When appropriate, 32D cells were 
pre-incubated for 3 h with caspase inhibitors. Viable cells were 
counted by a trypan blue exclusion assay. Cell survival was also de-
termined with the XTT test. In parallel, apoptosis was quantified by 
flow cytometry using FITC-Annexin V (0.3 \iglm\) [14] and CELL-
Quest software. 
2.3. Protease assays 
After stimulation, 32D cells were washed and resuspended in ice-
cold lysis buffer (50 mM HEPES (pH 7.5), 1 mM EDTA, 5 mM DTT, 
0.5% CHAPS, 10 μ^ιηΐ pefablock and 5 μ^ιηΐ leupeptin). After cen-
trifugation at lOOOOXg for 10 min at 4°C, supernatant was used for 
the caspase assay. Protease assays included 90 μΐ of reaction buffer 
(100 mM HEPES (pH 7.5), 10% sucrose, 0.1% CHAPS, 10 mM 
DTT), 10 μΐ of cell lysate (25 μg protein) and 50 μΐ of substrate 
(100 μΜ final concentration of YVAD-pNA or DEVD-pNA). Sam-
ples were incubated at 30°C for 30 min in a microtiter plate reader. 
Enzyme-catalyzed release of/)-nitroanilide was monitored at 405 nm. 
Under these conditions, conversion of the substrates was linear in 
time and amount of protein. 
3. Results and discussion 
To determine whether apoptosis in 32D cells is dependent 
on caspases, we generated 32D clones which stably overex-
press crmA. In parallel we also analyzed the effect of bcl-2 
overexpression, because the latter has been shown to regulate 
apoptosis and caspase activity in many cell lines [15]. Apop-
totic cell death was induced either by IL-3 deprivation or by 
ActD treatment and analyzed as described in Section 2. CrmA 
did not inhibit apoptosis induced by IL-3 deprivation or by 
Ac tD treatment (Table 1). In contrast, 32D+bcl-2 cells were 
markedly protected against cell death under both conditions. 
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Fig. 1. Time kinetics of apoptosis induced by IL-3 deprivation in 32D cells expressing either crmA ( τ ) , bcl-2 (■) or control vector ( · ) . Cells 
were IL-3 deprived for various time periods. Cell viability was determined by trypan blue exclusion and is expressed as the % trypan blue-nega-
tive cells compared to cells cultured in IL-3-supplemented medium. 
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Fig. 2. Dose-response curve of various caspase inhibitors on apoptotic death induced by IL-3 deprivation (A) or ActD treatment (B). Cell via-
bility was determined by XTT test. Experiments were performed in triplicate and % survival is expressed as % of 32D cells kept in IL-3-supple-
mented medium. ZVAD-fmk ( · ) ; DEVD-fmk (■); YVAD-cmk ( A ) . 
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Fig. 3. Effect of IL-3 deprivation and ActD on caspase activation. Lysates from 32D cells deprived of IL-3 (▼) or treated with ActD (·) for 
several time periods were assayed for protease activity towards DEVD-pNA. Data shown are from a single experiment and are representative 
of three independent experiments. 
Similar results were obtained when we quantified apoptotic 
death on the FACScan using Annexin V [14]. A 50% increase 
in Annexin V-positive cells was observed after IL-3 depriva-
tion for 24 h in empty vector or crmA-transfected 32D cells. 
However, no marked change in Annexin V-positive cells was 
detected in 32D+bcl-2 cells (data not shown). Analysis of the 
time kinetics of IL-3 withdrawal induced apoptosis revealed 
that the protective effect of bcl-2 expression reflects a delay of 
apoptosis rather than a complete inhibition of apoptosis (Fig. 
1). The finding that crmA has no effect on apoptosis in 32D 
cells induced by chemotherapy is consistent with studies from 
Datta et al. who recently reported that crmA does not inhibit 
apoptosis induced by ara-C and other chemotherapeutic 
agents in the myeloid leukemic cell line U937 [16]. 
Because crmA only inhibits specific members of the caspase 
family, several cell permeable synthetic caspase inhibitors were 
used to study the possible role of crmA-insensitive caspases in 
apoptosis of 32D cells. YVAD-cmk is a specific CASP-1 in-
hibitor, while DEVD-fmk is known to be an inhibitor of the 
CASP-3-like proteases. ZVAD-fmk has been described as a 
more general caspase inhibitor [3,17]. Fig. 2A shows that 
apoptosis induced by growth factor deprivation for 48 h is 
inhibited by increasing concentrations of ZVAD-fmk, but not 
by DEVD-fmk or YVAD-cmk. In contrast, ActD-induced cell 
death in 32D cells was prevented by ZVAD-fmk as well as 
Table 1 
Effect of CrmA or Bcl-2 expression on apoptosis induced by IL-3 
deprivation or ActD treatment in 32D cells 
% Survival 
Transfectant 
Empty vector 
CrmA 
Bcl-2 
-IL-3 
19 
18 
67 
+ActD 
16 
15 
65 
32D clones were IL-3 deprived for 24 h or treated with 1 μg/ml ActD 
for 18 h. Cell viability was determined by a XTT test. % Survival is 
expressed as % of the value obtained for cells growing in IL-3 supple-
mented medium (100%). Experiments were performed in triplicate. 
The SD was less than 10%. Similar results were obtained with inde-
pendent cell clones expressing either crmA or bcl-2. 
DEVD-fmk but not YVAD-cmk (Fig. 2B). These data dem-
onstrate that apoptosis induced by ActD treatment and by 
IL-3 deprivation is differentially mediated by DEVD-sensitive 
and DEVD-insensitive mechanisms, respectively. 
Caspase activity was subsequently assayed in lysates made 
from 32D cells that were treated with ActD or deprived of 
IL-3 for different time periods. CASP-1- and CASP-3-like 
activity was measured on the specific tetrapeptide substrates, 
YVAD-pNA and DEVD-pNA respectively. No clear protease 
activity towards YVDA-pNA was detected in lysates prepared 
from cells that were induced to undergo apoptosis by IL-3 
deprivation or ActD treatment (data not shown). In contrast, 
ActD treatment was associated with a marked increase in 
DEVD-pNA cleavage activity compared to apoptosis induc-
tion by IL-3 withdrawal which only marginally stimulated the 
cleavage of DEVD-pNA (Fig. 3). These findings of protease 
activation are consistent with the results obtained with the 
synthetic inhibitors as described above. 
In conclusion, the data in this study demonstrate that mem-
bers of the caspase family are involved in apoptosis of growth 
factor dependent myeloid leukemic cells. A crmA-insensitive 
mechanism is apparently involved in apoptosis induced by 
chemotherapy or by growth factor withdrawal in 32D cells. 
This is in contrast to Fas- and TNF-induced apoptosis, which 
occurs through a crmA-sensitive step [6]. Different capsases 
are activated during apoptosis induced by growth factor with-
drawal or by chemotherapy, since members of the CASP-3-
like proteases are clearly involved in apoptosis mediated by 
chemotherapy but not by IL-3 deprivation. CASP-1 is not 
activated upon any of the apoptotic stimuli. Further experi-
ments to elucidate the mechanism of this stimulus-dependent 
caspase activation are in progress. 
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